Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Gastric Cancer. 2019 Nov;22(6):1100-1108. doi: 10.1007/s10120-019-00950-y. Epub 2019 Mar 11.
Few reliable prognostic markers have been established despite elucidation of the molecular mechanisms of gastrointestinal stromal tumor (GIST) development. We evaluated F-box and WD repeat domain-containing 7 (FBXW7), a cell-cycle-regulating and tumor suppressor, in GISTs. We aimed to determine the clinical relevance of FBXW7 in GISTs and characterize the molecular mechanism of FBXW7 in a GIST cell line.
We measured FBXW7 expression in 182 GIST cases, correlated the expression levels with clinicopathological features, and characterized the molecular mechanism underlying suppressed FBXW7 expression in GIST cells in vitro.
Of the 182 GISTs, 98 (53.8%) and 84 (46.2%) were categorized in the high and low FBXW7 expression groups, respectively. Compared with the high FBXW7 expression group, the low expression group showed a significantly poorer prognosis in terms of recurrence-free (P = 0.01) and overall (P = 0.03) survival. FBXW7 expression was a significant independent factor affecting the 10-year recurrence-free survival rate (P = 0.04). In vitro, FBXW7-specific siRNAs enhanced c-myc and Notch 1 protein expression and upregulated cell proliferation, invasion, and migration.
FBXW7 is a potential predictive marker of recurrence after curative resection of GISTs. FBXW7 expression may help identify patients benefitting from adjuvant therapy more precisely compared with a conventional risk stratification model.
尽管阐明了胃肠道间质瘤(GIST)发展的分子机制,但仍未确立可靠的预后标志物。我们评估了 F-box 和 WD 重复结构域包含 7 号(FBXW7),一种细胞周期调节和肿瘤抑制因子,在 GIST 中的作用。我们旨在确定 FBXW7 在 GIST 中的临床相关性,并描述 FBXW7 在 GIST 细胞系中的分子机制。
我们测量了 182 例 GIST 病例中的 FBXW7 表达,将表达水平与临床病理特征相关联,并在体外研究中描述了 FBXW7 表达受抑制的分子机制。
在 182 例 GIST 中,98 例(53.8%)和 84 例(46.2%)分别归类为 FBXW7 高表达和低表达组。与 FBXW7 高表达组相比,低表达组在无复发生存(P=0.01)和总生存(P=0.03)方面的预后明显较差。FBXW7 表达是影响 10 年无复发生存率的独立显著因素(P=0.04)。在体外,FBXW7 特异性 siRNAs 增强了 c-myc 和 Notch 1 蛋白的表达,并上调了细胞增殖、侵袭和迁移。
FBXW7 是 GIST 根治性切除后复发的潜在预测标志物。与传统风险分层模型相比,FBXW7 表达可能有助于更准确地识别受益于辅助治疗的患者。